These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9508182)

  • 1. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
    Taylor CW; Green S; Dalton WS; Martino S; Rector D; Ingle JN; Robert NJ; Budd GT; Paradelo JC; Natale RB; Bearden JD; Mailliard JA; Osborne CK
    J Clin Oncol; 1998 Mar; 16(3):994-9. PubMed ID: 9508182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.
    Masuda N; Iwata H; Rai Y; Anan K; Takeuchi T; Kohno N; Takei H; Yanagita Y; Noguchi S
    Breast Cancer Res Treat; 2011 Apr; 126(2):443-51. PubMed ID: 21221770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
    Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
    J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
    Carlson RW; Theriault R; Schurman CM; Rivera E; Chung CT; Phan SC; Arun B; Dice K; Chiv VY; Green M; Valero V
    J Clin Oncol; 2010 Sep; 28(25):3917-21. PubMed ID: 20679610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
    Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
    Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
    J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
    Pritchard KI
    Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
    [No Abstract]   [Full Text] [Related]  

  • 14. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
    Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
    Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
    Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
    Cheer SM; Plosker GL; Simpson D; Wagstaff AJ
    Drugs; 2005; 65(18):2639-55. PubMed ID: 16392882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer.
    Noguchi S; Kim HJ; Jesena A; Parmar V; Sato N; Wang HC; Lokejaroenlarb S; Isidro J; Kim KS; Itoh Y; Shin E
    Breast Cancer; 2016 Sep; 23(5):771-9. PubMed ID: 26350351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.